OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.210
+0.010 (0.83%)
At close: Apr 28, 2026, 4:00 PM EDT
1.160
-0.050 (-4.13%)
After-hours: Apr 28, 2026, 5:54 PM EDT
OPKO Health Revenue
OPKO Health had revenue of $124.20M in the quarter ending March 31, 2026, a decrease of -17.18%. This brings the company's revenue in the last twelve months to $581.17M, down -15.70% year-over-year. In the year 2025, OPKO Health had annual revenue of $606.90M, down -14.90%.
Revenue (ttm)
$581.17M
Revenue Growth
-15.70%
P/S Ratio
1.51
Revenue / Employee
$266,760
Employees
2,275
Market Cap
918.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 606.90M | -106.24M | -14.90% |
| Dec 31, 2024 | 713.14M | -150.35M | -17.41% |
| Dec 31, 2023 | 863.50M | -140.71M | -14.01% |
| Dec 31, 2022 | 1.00B | -770.52M | -43.42% |
| Dec 31, 2021 | 1.77B | 339.31M | 23.64% |
| Dec 31, 2020 | 1.44B | 533.48M | 59.15% |
| Dec 31, 2019 | 901.94M | -88.33M | -8.92% |
| Dec 31, 2018 | 990.27M | 24.26M | 2.51% |
| Dec 31, 2017 | 966.01M | -151.48M | -13.56% |
| Dec 31, 2016 | 1.12B | 625.75M | 127.25% |
| Dec 31, 2015 | 491.74M | 400.61M | 439.63% |
| Dec 31, 2014 | 91.13M | -5.41M | -5.60% |
| Dec 31, 2013 | 96.53M | 49.49M | 105.19% |
| Dec 31, 2012 | 47.04M | 19.07M | 68.14% |
| Dec 31, 2011 | 27.98M | -515.00K | -1.81% |
| Dec 31, 2010 | 28.49M | 24.08M | 544.95% |
| Dec 31, 2009 | 4.42M | -5.02M | -53.20% |
| Dec 31, 2008 | 9.44M | 8.59M | 1,014.52% |
| Dec 31, 2007 | 847.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| NeoGenomics | 727.33M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| CareDx | 379.81M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 322.67M |
| BillionToOne | 305.11M |
OPK News
- 1 hour ago - OPKO Health Earnings Call Transcript: Q1 2026 - Transcripts
- 1 hour ago - OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results - GlobeNewsWire
- 6 days ago - OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas - GlobeNewsWire
- 7 days ago - OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 - GlobeNewsWire
- 2 months ago - OPKO Health to Participate in the Jefferies Biotech on the Beach Summit - GlobeNewsWire
- 2 months ago - OPKO Health Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewsWire